AGGRENOX
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASEPriority Review
Approved
Nov 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
4/8 — Partial
Priority Review
AGGRENOX by Boehringer Ingelheim is 12. Approved for stroke in patients, completed ischemic stroke due to thrombosis. First approved in 1999.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGGRENOX is a fixed-dose combination of dipyridamole and aspirin delivered as an extended-release oral capsule. It prevents stroke in patients with a history of completed ischemic stroke due to thrombosis by combining additive antiplatelet effects through dual mechanisms: adenosine reuptake inhibition and cyclooxygenase inhibition. The synergistic action reduces platelet aggregation more effectively than either agent alone.
LOE Approaching
LOE-approaching status signals potential restructuring of the brand team; career growth limited without major indication expansion or new formulation pipeline.
Mechanism of Action
12.1 Mechanism of Action The antithrombotic action of AGGRENOX is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo ; the inhibition occurs…
Worked on AGGRENOX at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.